Which laboratory tests are commonly reviewed to monitor medication safety in older adults on chronic therapy?

• A. Vitamin C level only.
• B. Renal function (creatinine/eGFR), electrolytes (Na/K), liver enzymes (AST/ALT), HbA1c, lipid panel as indicated.
• C. Brain imaging studies.
• D. Urinalysis only.

Answer: (B)

In older adults on long-term therapy, monitoring safety hinges on labs that show how the body handles drugs and where adverse effects may arise. Renal function matters because the kidneys often clear medications and metabolites; a lower eGFR or rising creatinine means drugs can accumulate and cause toxicity, so dosing and choice of meds are guided by kidney function. Electrolyte levels are key since many medications influence sodium and potassium balance, and imbalances can be dangerous in the elderly. Liver enzymes reflect hepatic metabolism and potential hepatotoxicity, helping detect impaired drug processing or the need to adjust doses for drugs processed by the liver. HbA1c provides a longer-term view of glucose control, which is important if the patient has diabetes or is on meds that affect blood sugar. A lipid panel, used as indicated, supports monitoring when lipid-lowering therapy is involved or when medications might impact lipid metabolism or interact with other regimens. Together, these labs give a comprehensive view of organ function and metabolic status relevant to safe chronic medication use. Brain imaging or urinalysis alone aren’t routine measures for monitoring medication safety in this context, and vitamin C level isn’t a standard monitoring parameter for chronic therapies.